Annals of Hematology

Article	Citations
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry	126
Hematologic disorders associated with COVID-19: a review	59
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes	54
Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies	52
Impact of rituximab on COVID-19 outcomes	47
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working	46
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy	44
Hematologic changes predict clinical outcome in recovered patients with COVID-19	42
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the Ge	36
Hemolytic anemia in COVID-19	35
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for	33
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes	33
Concise review: how do red blood cells born, live, and die?	32
Castleman disease and TAFRO syndrome	32
Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database	30
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data	30
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey	30
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation	30
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation	30
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?	28
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial	28
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies	26
The emerging therapeutic landscape of relapsed/refractory multiple myeloma	25
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives	25
Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125	25

Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis	24
COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications	24
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort	24
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval	24
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US	23
Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study	23
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine	22
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia	21
Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review	21
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study	21
G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?	20
Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia	20
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review	20
Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial	20
Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis	20
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab	19
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria	19
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies	19
Skin changes in hairy cell leukemia	19
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience	18
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)	18
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis	18
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study	18
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry	18
Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement	17
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia	17
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study	17
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms	17
Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome	16
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials	16
Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals	16
Supportive and palliative care in hemato-oncology: how best to achieve seamless integration and subspecialty development?	16
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data	16
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia	15
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis	15
Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management	15
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes—results of a retrospective analysis from a German university	14
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib	14
Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue	14
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience	14
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience	14
Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major	14
Acute lymphoblastic leukemia–like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients	14
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophos	14
Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse ris	14
Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation	14
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)	14
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies	14
Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies	14
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report	14

Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Gro	13
Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa	13
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients	13
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis	13
Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review	13
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma	12
Clinical association between thyroid disease and immune thrombocytopenia	12
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation	12
Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives	12
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma	12
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)	12
Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis	12
Tissue factor–bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study	12
Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in sickle cell disease and its association with disease-related morbidities	12
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells	12
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma	12
L-glutamine for sickle cell disease: more than reducing redox	12
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of	12
Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy	12
Amyloidosis and COVID-19: experience from an amyloid program in Canada	11
Phase II study of single-agent nivolumab in patients with myelofibrosis	11
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis	11
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience	11
Real-world treatments and thrombotic events in polycythemia vera patients in the USA	11
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma	11
Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells	11
Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination	11
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016	11
Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study	11
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab	11
Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation	11
Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma	11
Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study	10
Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort	10
ADAMTS-13–VWF axis in sickle cell disease patients	10
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies	10
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study	10
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-ye	10
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants	10
Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma	10
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world d	10
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma	10
Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis	10
Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting	10
Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis	10
Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation	10
High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease	10
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era	10
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study	9
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase	9
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study	9
Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India	9
Long-term outcome after allogeneic stem cell transplantation in multiple myeloma	9
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes	9
Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA	9
PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial	9
Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin	9
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients	9
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study	9
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases	9
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma	9
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center	9
Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era	9
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients	9
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease	9
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years	9
Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis	9
Opioids are not a major cause of death of patients with sickle cell disease	9
Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia	9
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma	9
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns	9
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients	9
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K	9
Possible nosocomial transmission of virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation	9
Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019)	8
Characteristics and survival trends in Finnish multiple myeloma patients—a nationwide real-world evidence study	8
Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II–IV acute graft-versus-host disease in allogeneic hematopoietic stem cel	8
Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis	8
The anemia-independent impact of myelodysplastic syndromes on health-related quality of life	8
Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera	8

Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments	8
Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program	8
Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation	8
Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis	8
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO)	8
Treatment for relapsed acute promyelocytic leukemia	8
Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation	8
Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease	8
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group	8
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis	8
Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies	8
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients	8
Peripherally inserted central venous catheters decrease central line-associated bloodstream infections and change microbiological epidemiology in adult hematology unit: a propensity score-adjusted ana	8
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis	8
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients	8
Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing	8
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation	8
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort	8
Oral therapy adherence and satisfaction in patients with multiple myeloma	8
Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes	8
Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide	8
CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia	8
Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis	8
Characteristics of Sweet syndrome in patients with or without malignancy	8
Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis	8
Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation	8
Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis	8
Successful treatment of Kimura disease with benralizumab	7
A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma	7
Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation	7
Circulating low CD4+/CD8+ ratio is associated with poor prognosis in Waldenstrom macroglobulinemia patients	7
Extracorporeal membrane oxygenation in patients with hematologic malignancies: a systematic review and meta-analysis	7
The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma	7
Diagnosis and management of non-clonal erythrocytosis remains challenging: a single centre clinical experience	7
A real-world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia	7
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group	7
Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma	7
Serum cytokine pattern in children with hemophagocytic lymphohistiocytosis	7
Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy	7
Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement	7
Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens	7
TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review	7
CD37 expression in follicular lymphoma	7
VEXAS syndrome: complete molecular remission after hypomethylating therapy	7
Successful treatment of hairy cell leukemia variant with obinutuzumab	7
Hepatocellular carcinoma in patients with thalassemia in the post-DAA era: not a disappearing entity	7
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma	7
Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study	7
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study	7
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis	7
Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study	7
Circulating tumor DNA in Hodgkin lymphoma	7
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera	7
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial	7
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials	7
Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6–7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor i	7
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasms	7
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study	7
Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia	7
Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenita	6
Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia	6
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy	6
Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort	6
R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience	6
Langerhans cell histiocytosis in adults: a retrospective, single-center case series	6
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab	6
Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)	6
Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience	6
First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years’ experience	6
Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease	6
CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2+ T cell cytotoxicity	6
Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy	6
Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients	6
Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan	6
Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level	6
Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study	6
Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy	6
Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study	6
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”	6
Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese children	6
Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL	6
Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings	6
Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience	6
Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol	6
Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients	6
ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution	6
δ-Hemoglobinopathies in Thailand: screening, molecular basis, genotype-phenotype interaction, and implication for prevention and control of thalassemia	6
Epstein–Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non–Hodgkin lymphoma: the prevalence and impacts on outcomes	6
Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia	6
Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India	6
HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19	6
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study	6
Blood and platelet transfusion from a donor with presymptomatic Covid-19	6
Real-world experience of anti-D immunoglobulin in immune thrombocytopenia	6
Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value	6